TZ9

TZ9 is a selective Rad6 inhibitor. TZ9 inhibits Rad6B -induced histone H2A ubiquitination, downregulates intracellular β-catenin , induces G2-M arrest and apoptosis , and inhibits the proliferation and migration of metastatic human breast cancer cells. In Vitro TZ9 (Rad6B SMI #9) (0.5-100 µM; 72 h) inhibits MDA-MB-231 cell proliferation and migration. TZ9 (0.1-5 µM; 24-72 h) delays cell-cycle progression in MDA-MB-231 cells. TZ9 (5 µM; 8-48 h) induces apoptosis in MDA-MB-231 cells. TZ9 (0.5, 1, 2.5, 5 µM; 24 h) inhibits H2A ubiquitination and downregulates levels of PCNA and β-catenin protein in MDA-MB-231 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: MDA-MB-231 cells Concentration: 0.5-100 µM Incubation Time: 72 h Result: Inhibited MDA-MB-231 cell proliferation with IC 50 ~6µM. Apoptosis AnalysisCell Line: MDA-MB-231 cells Concentration: 5 µM Incubation Time: 8-48 h Result: Induced cells apoptosis. Cell Cycle AnalysisCell Line: MDA-MB-231 cells Concentration: 0.1-5 µM Incubation Time: 24-72 h Result: Increased the proportion of G2-M-arrested cells by 2-fold and was accompanied by a proportional decrease in S-phase cells when at 24 h. Significantly increased the percentage of cells with cytoplasmic/nuclear cyclin B1 staining. Western Blot AnalysisCell Line: MDA-MB-231 cells Concentration: 0.5, 1, 2.5, 5 µM Incubation Time: 24 h Result: Inhibited H2A ubiquitination, decreased PCNA and β-catenin protein levels. Form:Solid

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet